We aim to test how well modern nonhabitual barefoot people can adapt to barefoot and Minimalist Bare Foot Technology (MBFT) shoes, in regard to gait symmetry. 28 healthy university students (22 females/6 males) were recruited to walk on a 10-meter walkway randomly on barefoot, in MBFT shoes, and in neutral running shoes at their comfortable walking speed. Kinetic and kinematic data were collected using an 8-camera motion capture system. Data of joint angles, joint forces, and joint moments were extracted to compute a consecutive symmetry index. Compared to walking in neutral running shoes, walking barefoot led to worse symmetry of the following: ankle joint force in sagittal plane, knee joint moment in transverse plane, and ankle joint moment in frontal plane, while improving the symmetry of joint angle in sagittal plane at ankle joints and global (hip-knee-ankle) level. Walking in MBFT shoes had intermediate gait symmetry performance as compared to walking barefoot/walking in neutral running shoes. We conclude that modern nonhabitual barefoot adults will lose some gait symmetry in joint force/moment if they switch to barefoot walking without fitting in; MBFT shoe might be an ideal compromise for healthy youth as regards gait symmetry in walking.

No abstract

No abstract

No abstract

groups using generalized estimating equations. Results: The final study sample included 5,768 patients for each treatment group (mean age=66.5 years [SD=11.2]; 66% males). In both Floseal, and Surgiflo Ò groups, approximately 31% of patients required blood transfusions within 0-1 days [odds ratio (OR): 1.04; 95% confidence interval (CI): 0.97-1.11)] and 7% within 2-4 days (OR: 1.02; 95%CI: 0.90-1.16) of surgery. Compared to Floseal, Surgiflo Ò patients had 11% higher ICU admissions (OR: 1.68; 95%CI: 1.56-1.80), longer surgery duration (306 vs. 299 minutes, P,0.05), an average of $2,682 lower hospitalization cost ($44,146 vs. $46,828 P,0.05), and a significantly lower risk of readmission at 30-60-90 days post-discharge (27%, 13% and 12% less likely respectively; all p,0.05). Other outcomes including bleeding, mortality and LOS were comparable (P.0.05). Conclusions: This study included a large sample of patients undergoing cardiovascular surgery over the past 7 years. The results focus on newer hemostatic matrix formulations and suggest relatively comparable clinical outcomes across products. Additionally, these results suggest lower overall hospitalization costs for Surgiflo Ò compared to Floseal.